Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

ER-low Expressors Experience Benefit With Trastuzumab Deruxtecan in DESTINY-Breast04 Subgroup Analysis

May 12th 2023

Fam-trastuzumab deruxtecan-nxki was associated with better efficacy outcomes compared with treatment of physician’s choice in patients with HER2-low, estrogen receptor-low metastatic breast cancer, according to findings from a subgroup analysis of the phase 3 DESTINY-Breast04 study.

Hormonal Maintenance Therapy Offers Deescalated Option for Low-Grade Serous Ovarian Cancers

May 12th 2023

Patients with low-grade serous ovarian carcinoma historically have demonstrated a benefit with hormonal maintenance therapy following cytoreductive surgery and platinum-based chemotherapy.

Trastuzumab Deruxtecan Elicits Superior HRQOL in HER2+ Metastatic Breast Cancer

May 11th 2023

Patient-reported outcomes with fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial, according to findings presented during the 2023 ESMO Breast Cancer Annual Congress.

Decentralization Efforts Could Engage Community Oncologists

May 9th 2023

As more treatment options enter the oncology landscape, access to these life-changing medicines has become a paramount concern.

Individual Patient Factors Drive Treatment Decisions in MPNs

May 4th 2023

Onco-nursing experts highlight the best practices and latest treatment regimens for patients presenting with the 3 most common myeloproliferative neoplasms: myelofibrosis, polycythemia vera, and essential thrombocythemia.

Novel KRAS G12C Inhibitor Shows Early Signs of Efficacy Across Solid Tumors, Pretreated NSCLC

April 17th 2023

LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Selective CDK2 Inhibitor Undergoes Investigation in CCNE1-High Tumors

April 17th 2023

Preclinical data have demonstrated activity of a novel, small molecule CDK2 inhibitor INCB123667 in CDK2/cyclin E1 expressing cell lines prompting investigators to initiate a phase 1 study, and the agent may fill an unmet need for patients with cancers with primary or acquired CDK4/6 resistance.

Trastuzumab Deruxtecan Displays Antitumor Activity, Safety in HER2-Expressing Uterine Carcinosarcoma

April 14th 2023

The antibody-drug conjugate trastuzumab deruxtecan led to durable responses and a tolerable safety profile in patients with HER2-expressing uterine carcinosarcoma.

PD-1/CTLA-4 Combination Drives Progress Across Tumor Types

April 14th 2023

Investigators of an ongoing phase 1a/1b multicohort trial are studying whether addition of adaptive immune activators increases the benefit derived from anti–PD-1 antibodies in multiple tumor types.

Actionable Subsets of Patients With CRC Drive Progress

April 12th 2023

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

Encouraging Data Pave the Way for New Standards in CRC

March 29th 2023

As the development of systemic treatments for metastatic colorectal cancer move toward precision therapy, guidelines have adjusted to integrate decisions based on molecular drivers.

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

Frontline treatments that achieve transfusion independence are of paramount importance for patients with lower-risk myelodysplastic syndrome.

Coleman Illuminates Opportunities in Gynecologic Malignancies

March 17th 2023

Robert L. Coleman, MD, FACOG, FACS, the 2020 Giants of Cancer Care® award winner in gynecologic malignancies, notes that despite the great progress in the past decade, more work is needed to personalize and refine approaches to care.

New Generation of TKIs Challenge Standards of Care in Newly Diagnosed Ph+ ALL

March 7th 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

Real-World Outcomes With Sacituzumab Govitecan Match ASCENT in Single-Center Study

March 5th 2023

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.

Miami Breast Keynotes Highlight the Call to Action for Advocacy Efforts in Breast Cancer

March 4th 2023

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

SERMS, SERDS, and PROTEC Are Poised to Shake Up Treatments for ER+ Breast Cancer

March 4th 2023

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

HER2-Low Expression is the Tip of the Iceberg in Breast Cancer Classification

March 3rd 2023

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

Miami Breast Cancer Conference Celebrates 40 Years

March 3rd 2023

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

Resistance Mutations Present an Ongoing Challenge in Aggressive Hematologic Malignancies

February 28th 2023

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.